Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B^™ Cell Therapy Through Levels of Vascular Biomarker

Longeveron, Inc. announced that the European Patent Office has issued a notice of its intent to grant the company a patent related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic mesenchymal cell therapies, also known as medicinal signaling cells.